|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.49 USD | +0.03% |
|
0.00% | +34.92% |
| 07-16 | Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals | MT |
| 07-16 | Deals of the day-Mergers and acquisitions | RE |
| Market Cap | 3.85B 3.39B 3.15B 2.89B 5.43B 371B 5.51B 37.39B 14.61B 183B 14.47B 14.16B 631B | P/E 2026 * |
16.6x | P/E 2027 * | 13.9x |
|---|---|---|---|---|---|
| Enterprise Value | 3.85B 3.39B 3.15B 2.89B 5.43B 371B 5.51B 37.39B 14.61B 183B 14.47B 14.16B 631B | EV / Sales 2026 * |
6.1x | EV / Sales 2027 * | 5.43x |
| Free-Float |
99.94% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Catalyst Pharmaceuticals, Inc.
| 1 day | +0.03% | ||
| Current month | +0.19% | ||
| 1 month | +0.22% | ||
| 3 months | +15.05% | ||
| 6 months | +33.55% | ||
| Current year | +34.92% |
| 1 month | 31.41 |  | 31.5 |
| Current year | 22.13 | | 32.56 |
| 1 year | 19.05 | | 32.56 |
| 3 years | 11.55 | | 32.56 |
| 5 years | 4.81 | | 32.56 |
| 10 years | 0.68 | | 32.56 |
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Daly
CEO | Chief Executive Officer | 65 | 01/01/2024 |
Michael Kalb
DFI | Director of Finance/CFO | 55 | 01/01/2024 |
William Andrews
CTO | Chief Tech/Sci/R&D Officer | 62 | 01/06/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 48 | 15/07/2026 | |
Massimo Marin
BRD | Director/Board Member | - | 15/07/2026 |
Enrica Dogali
BRD | Director/Board Member | - | 15/07/2026 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 15/7/26 | Issuer sale | Chief Executive Officer | -2,889,805 | 2.3606% | ||
| 15/7/26 | Issuer sale | Chief Financial Officer | -646,568 | 0.5282% | ||
| 15/7/26 | Issuer sale | Director | -130,857 | 0.1069% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | 0.00% | +49.81% | +132.57% | 3.85B | |
| +0.63% | -3.06% | +16.18% | -9.78% | 66.74B | |
| +1.23% | +2.80% | +37.51% | +202.14% | 53.32B | |
| +10.08% | +51.80% | +51.80% | +51.80% | 48.12B | |
| -1.32% | -7.38% | -57.63% | -57.10% | 38.25B | |
| +0.78% | -1.84% | +52.49% | -27.01% | 29.85B | |
| +0.84% | +0.36% | +66.93% | +85.42% | 23.51B | |
| -5.17% | -12.54% | +58.98% | -56.04% | 21.45B | |
| -1.21% | +1.12% | +1.98% | +170.93% | 19.97B | |
| -0.22% | -0.95% | +61.97% | +123.78% | 16.38B | |
| Average | +1.16% | -0.90% | +34.00% | +61.67% | 32.14B | |
| Weighted average by Cap. | +1.79% | -0.11% | +28.06% | +50.97% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 632M 555M 516M 474M 890M 60.88B 904M 6.13B 2.4B 29.93B 2.37B 2.32B 103B | 709M 623M 579M 532M 999M 68.32B 1.01B 6.88B 2.69B 33.59B 2.66B 2.61B 116B |
| Net income | 231M 203M 189M 173M 326M 22.26B 331M 2.24B 876M 10.94B 868M 849M 37.84B | 279M 245M 228M 209M 393M 26.85B 399M 2.7B 1.06B 13.2B 1.05B 1.02B 45.64B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- CPRX Stock
Select your edition
All financial news and data tailored to specific country editions
